|
Neoplastic Cell Transformation
|
0.300 |
Therapeutic
|
phenotype |
CTD_human |
Poly(ADP-Ribose) Glycohydrolase (PARG) Silencing Suppresses Benzo(a)pyrene Induced Cell Transformation.
|
27003318 |
2016 |
|
Neoplastic Cell Transformation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Poly(ADP-Ribose) Glycohydrolase (PARG) Silencing Suppresses Benzo(a)pyrene Induced Cell Transformation.
|
27003318 |
2016 |
|
Neoplastic Cell Transformation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Poly(ADP-ribose) glycohydrolase silencing down-regulates TCTP and Cofilin-1 associated with metastasis in benzo(a)pyrene carcinogenesis.
|
25628927 |
2015 |
|
Neoplastic Cell Transformation
|
0.300 |
Therapeutic
|
phenotype |
CTD_human |
Poly(ADP-ribose) glycohydrolase silencing down-regulates TCTP and Cofilin-1 associated with metastasis in benzo(a)pyrene carcinogenesis.
|
25628927 |
2015 |
|
Blastocyst Disintegration
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality.
|
15591342 |
2004 |
|
Embryo Resorption
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality.
|
15591342 |
2004 |
|
Embryo Death
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality.
|
15591342 |
2004 |
|
Embryo Loss
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality.
|
15591342 |
2004 |
|
Embryo Disintegration
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality.
|
15591342 |
2004 |
|
Borna Disease
|
0.200 |
Biomarker
|
disease |
RGD |
Hippocampal poly(ADP-Ribose) polymerase 1 and caspase 3 activation in neonatal bornavirus infection.
|
18057239 |
2008 |
|
Brain Infarction
|
0.200 |
Biomarker
|
disease |
RGD |
We demonstrate that either pre- or post-ischemia treatment with 40 mg/kg of N-bis-(3-phenyl-propyl)9-oxo-fluorene-2,7-diamide, a novel PARG inhibitor, significantly reduces brain infarct volumes by 40-53% in a rat model of focal cerebral ischemia.
|
12834903 |
2003 |
|
Glomerular Filtration Rate
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A catalog of genetic loci associated with kidney function from analyses of a million individuals.
|
31152163 |
2019 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Poly(ADP-ribose)ylation (PARylation) by PAR polymerase 1 (PARP1) and PARylation removal by poly(ADP-ribose) glycohydrolase (PARG) critically regulate DNA damage responses; yet, conflicting reports obscure PARG biology and its impact on cancer cell resistance to PARP1 inhibitors.
|
31827085 |
2019 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Taken together, these results indicate that <i>DUSP22</i> deficiency exerts a synthetic lethal effect when combined with PARG dysfunction, suggesting that DUSP22 dysfunction could be a useful biomarker for cancer therapy using PARG inhibitors.
|
31142510 |
2019 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Furthermore, the induction of apoptosis code of DNA replication catastrophe by synthetic lethality of PARG inhibition and the recent progresses regarding the development of small molecule PARG inhibitors and their therapeutic potentials in cancer chemotherapy are highlighted in this review.
|
31176615 |
2019 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Our results highlight the HuR-PARG axis as an opportunity to enhance PARPi-based therapies.<i>Cancer Res; 77(18); 5011-25.©2017 AACR</i>.
|
28687616 |
2017 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
This was the first study that reported evidences to support an oncogenic role of PARG in BaP induced carcinogenesis, which provided a new perspective for our understanding in BaP exposure induced cancer.
|
27003318 |
2016 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Hence, this study emphasizes and converges on the relevance of silencing PARG which inhibits growth of human colonic cancer cells via PI3K/Akt/NFκ-B pathway; as colon carcinoma remains to be amongst one of the commonest cancers throughout the world with high morbidity and mortality rates.
|
21713600 |
2012 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Furthermore, accumulating experimental evidence supports the utility of PARP and PARG inhibitors in cancer therapy and several clinical trials are now ongoing.
|
17645773 |
2007 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
In this brief review on PARP and PARG enzymes, emphasis is placed on PARP-1, the best understood member of the PARP family and on the relationship of poly(ADP-ribosyl)ation to cancer and other diseases of aging.
|
15743666 |
2005 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Further analysis of PARP-1, PARG and other PARP family genes should extend our understanding of the pathogenesis of cancer and autoimmune diseases.
|
15868402 |
2005 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
Taken together, these results indicate that <i>DUSP22</i> deficiency exerts a synthetic lethal effect when combined with PARG dysfunction, suggesting that DUSP22 dysfunction could be a useful biomarker for cancer therapy using PARG inhibitors.
|
31142510 |
2019 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
Poly(ADP-ribose)ylation (PARylation) by PAR polymerase 1 (PARP1) and PARylation removal by poly(ADP-ribose) glycohydrolase (PARG) critically regulate DNA damage responses; yet, conflicting reports obscure PARG biology and its impact on cancer cell resistance to PARP1 inhibitors.
|
31827085 |
2019 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
Furthermore, the induction of apoptosis code of DNA replication catastrophe by synthetic lethality of PARG inhibition and the recent progresses regarding the development of small molecule PARG inhibitors and their therapeutic potentials in cancer chemotherapy are highlighted in this review.
|
31176615 |
2019 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
Our results highlight the HuR-PARG axis as an opportunity to enhance PARPi-based therapies.<i>Cancer Res; 77(18); 5011-25.©2017 AACR</i>.
|
28687616 |
2017 |